CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Rhea-AI Summary

Cumberland Pharmaceuticals (Nasdaq: CPIX) will release its Q2 2026 financial results and a broader company update after market close on Tuesday, August 4, 2026. Management will host a conference call at 4:30 p.m. Eastern Time that day, with replay available for one year.

Cumberland describes itself as a Tennessee-based biopharmaceutical company focused on innovative treatments for rare diseases. According to the company, its late-stage Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis.

Market Context

Across two prior earnings-date announcements, CPIX recorded an average 24-hour move of 1.48%. That r...

Analysis

Across two prior earnings-date announcements, CPIX recorded an average 24-hour move of 1.48%. That record adds a mixed historical benchmark to this scheduling notice; the August 4 results remain the key disclosed follow-up, with low short positioning as a risk context.

Key Figures

Reporting period: Q2 2026 Announcement date: July 28, 2026 Results date: August 4, 2026 +3 more

6 metrics

Reporting period Q2 2026 Financial results scheduled for release

Announcement date July 28, 2026 Company announcement date

Results date August 4, 2026 Results and company update scheduled after market close

Conference call time 4:30 p.m. Eastern Time Conference call scheduled for August 4

Replay availability one year Conference call replay availability

Clinical program phase Phase 2 Ifetroban programs across multiple diseases

Previous Earnings date Reports

2 past events · Latest: Apr 28 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 28	Q1 earnings date	Neutral	-1.6%	Scheduled Q1 results and company update for release after market close
Feb 24	Annual earnings date	Neutral	+4.6%	Scheduled annual results and company update for release after market close

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The two prior earnings-date notices produced mixed 24-hour reactions, from -1.64% to +4.59%, rather than a consistent direction.

Key Terms

phase 2, duchenne muscular dystrophy, systemic sclerosis, idiopathic pulmonary fibrosis

4 terms

phase 2 medical

"Cumberland's Phase 2 clinical programs are evaluating ifetroban"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

duchenne muscular dystrophy medical

"ifetroban in patients with Duchenne Muscular Dystrophy"

A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.

systemic sclerosis medical

"Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis"

Systemic sclerosis is a chronic autoimmune disease where the body's repair system overreacts, causing hardening and tightening of skin and internal organs much like scar tissue spreading beyond a wound. It matters to investors because it creates a clear medical need for new treatments, influences the size and urgency of clinical trials, and affects regulatory scrutiny, pricing power, and long-term healthcare costs tied to any therapy or diagnostic that proves effective.

idiopathic pulmonary fibrosis medical

"Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NASHVILLE, Tenn., July 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, announced today that it will provide a company update with second quarter 2026 financial results after the market closes on Tuesday, August 4, 2026.

A conference call will be held on August 4 at 4:30 p.m. Eastern Time to discuss the results and update.

Call Participation

The link to register is https://register-conf.media-server.com/register/BI2da176d5d0dd4778a44db3d4af6e7b39.

Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically
call them at the start of the conference.

A replay of the call will be available for one year and can be accessed via the Investor Relations page of Cumberland's website or by visiting https://edge.media-server.com/mmc/p/xokd879m.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on developing innovative products that improve the quality of patient care. The company is advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs.

Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis.

For more information, please visit www.cumberlandpharma.com.

 

View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-company-update--q2-2026-financial-results-302836258.html

SOURCE Cumberland Pharmaceuticals Inc.

FAQ

When will Cumberland Pharmaceuticals (CPIX) report its Q2 2026 financial results?

Cumberland Pharmaceuticals plans to report its Q2 2026 financial results on Tuesday, August 4, 2026, after the market closes. According to Cumberland, the release will be accompanied by a company update and an investor conference call that same afternoon.

What time is the Cumberland Pharmaceuticals (CPIX) Q2 2026 earnings conference call on August 4, 2026?

The Cumberland Pharmaceuticals Q2 2026 earnings conference call is scheduled for 4:30 p.m. Eastern Time on August 4, 2026. According to Cumberland, the call will review financial results and provide a broader update on company activities and programs.

How can investors access the Cumberland Pharmaceuticals (CPIX) Q2 2026 earnings call and webcast?

Investors can register at the provided webcast link to receive a dial-in number and PIN or use a “Call Me” option. According to Cumberland, a replay will be available for one year via the Investor Relations section of its website and the replay link.

Will there be a replay of the Cumberland Pharmaceuticals (CPIX) Q2 2026 results conference call?

Yes, a replay of the Cumberland Pharmaceuticals Q2 2026 conference call will be available for one year. According to Cumberland, investors can access it through the company’s Investor Relations webpage or directly via the specified media-server replay link.

What clinical programs is Cumberland Pharmaceuticals (CPIX) advancing as of the Q2 2026 update?

Cumberland is advancing late-stage Phase 2 programs evaluating ifetroban in several serious conditions. According to Cumberland, these include Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis, reflecting its focus on significant unmet medical needs.

What type of company is Cumberland Pharmaceuticals (CPIX) and where is it headquartered?

Cumberland Pharmaceuticals is a biopharmaceutical company focused on innovative products that improve patient care, especially for rare diseases. According to Cumberland, it is the largest biopharmaceutical company founded and headquartered in Tennessee, with multiple late-stage clinical programs in development.